UK: NICE’s Rare Disease Gatekeeping Comes Under The Microscope
Executive Summary
A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.
You may also be interested in...
UK’s NICE Namuscla Decision A ‘Red Flag’ For Repurposed Medicines
Lupin and patient groups have slammed NICE’s “unprecedented” preliminary decision not to mandate funding for the repurposed rare disease treatment Namuscla for patients on England’s National Health Service who are already taking the drug. The move could set a precedent and is concerning for patients and R&D investments, says the company.
Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.
UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug
A decision by England’s High Court to reject claims that HTA body NICE acted unlawfully when evaluating BioMarin’s PKU treatment has quashed hopes that NICE’s Highly Specialized Technologies program will become more widely used to evaluate rare disease treatments. Lawyers representing a PKU patient are planning to appeal the judgement.